https://en.bioecon.ru/technologies/crispr-cas9/Recent content in Crispr-Cas9 on BioeconHugoen-USWed, 29 Jul 2026 13:42:49 +0700https://en.bioecon.ru/technology/genetic-design-ornamental-landscape-plants/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genetic-design-ornamental-landscape-plants/Genetic engineering of ornamental plants and landscape trees for novel traits, bioluminescence, and urban air purification.https://en.bioecon.ru/technology/genetic-engineering-bio-selection/Sun, 28 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genetic-engineering-bio-selection/Advanced crop breeding utilizing genomic selection, CRISPR-Cas9, and marker-assisted breeding for high-yield, resilient seeds.https://en.bioecon.ru/technology/biofortification-of-crops/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biofortification-of-crops/Breeding and genetically engineering staple crops to naturally accumulate higher levels of essential vitamins and minerals, addressing global hidden hunger.https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.